Indiana Seed Fund makes 11th investment

Back to TopCommentsE-mailPrintBookmark and Share

BioCrossroads’ $6 million Indiana Seed Fund has made its 11th investment—$250,000 in Indianapolis-based Aarden Pharmaceuticals.

Aarden focuses on intracellular disease targets, with its lead program focused on treating tuberculosis.

The work spun out of the research by Zhong-Zin Zhang, a professor and chairman of biochemistry and molecular biology at the Indiana University School of Medicine.

Zhang is an expert in protein tyrosine phosphates, a group of signaling enzymes that regulate cellular processes. His research was funded through Lilly Endowment’s Indiana Genomics Initiative, or INGEN.

“Aarden’s promising science, pre-eminent research and outstanding leadership team illustrate very well the full promise of the grant,” said David Johnson, president and CEO of BioCrossroads.

The BioCrossroads investment will help accelerate progress on the TB program through the pre-clinical stage, said Aarden’s CEO, Gary Noonan.

Other work by Aarden, in cancer and autoimmune therapies, is in pre-clinical testing.

The company decided last year to establish its headquarters here, selecting Indianapolis over San Diego.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ